

Published in final edited form as:

Bioorg Med Chem. 2014 March 15; 22(6): 1889–1898. doi:10.1016/j.bmc.2014.01.052.

## Cytotoxic cardiac glycosides and coumarins from *Antiaris toxicaria*

Li-Shian Shi<sup>a,b</sup>, Sheng-Chu Kuo<sup>c</sup>, Han-Dong Sun<sup>d</sup>, Susan L. Morris-Natschke<sup>e</sup>, Kuo-Hsiung Lee<sup>e,f</sup>, and Tian-Shung Wu<sup>b,e,\*</sup>

<sup>a</sup>Department of Biotechnology, National Formosa University, Yunlin 632, Taiwan

<sup>b</sup>Department of Chemistry, National Cheng Kung University, Tainan 701, Taiwan

<sup>c</sup>Graduate Institute of Pharmaceutical Chemistry, China Medical University, Taichung 401, Taiwan

<sup>d</sup>Kunming Institute of Botany, Chinese Academy of Science, Kunming 650204, Yunnan, China

<sup>e</sup>Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7568, USA

<sup>f</sup>Department of Pharmacy and Chinese Medicine Research and Development Center, China Medical University, Taichung 401, Taiwan

### Abstract

Eight new cardiac glycosides/aglycones (antiarrhythmics A–G, **1–7**, and antiarrhythmoxin B, **8**), two new coumarins (anticarins A–B, **41–42**), and two new flavanones (antiarrones L–K, **43–44**) were isolated from trunk bark of *Antiaris toxicaria* together with 53 known compounds. The new structures were established by extensive analysis of spectroscopic data. Compound **1** (10-carboxy and 3 $\alpha$ -hydroxy) and compounds **3–6** (10-hydroxy) contain unique substituents that are rarely found in cardiac glycosides. The cytotoxic effects of isolated compounds against ten human cancer cell lines, KB, KB-VIN, A549, MCF-7, U-87-MG, PC-3, 1A9, CAKI-1, HCT-9 and S-KMEL-2, were tested using the sulforhodamine B assay. Five compounds (**12**, **16**, **20**, **22**, and **31**) showed significant cytotoxicity against all ten cancer cell lines, with notable potency at the ng/mL level against some cell lines, which merits further development as clinical trial candidates.

### Keywords

Antiaris toxicaria; Cardiac glycosides; Coumarins; Cytotoxicity

### 1. Introduction

Cardiac glycosides are naturally occurring compounds with a steroidal framework and are used for the treatment of congestive heart failure and as anti-arrhythmic agents. They also have been used as arrow poisons, abortifacients, emetics, diuretics, and heart tonics.<sup>1</sup>

Mechanistically, their anti-arrhythmic activity results from inhibition of Na<sup>+</sup>/K<sup>+</sup>-ATPase, and leads to an increased intracellular calcium concentration. Recent research indicated that binding of cardiac glycosides to Na<sup>+</sup>/K<sup>+</sup>-ATPase can activate multiple downstream signal transduction pathways that regulate many important physiological and pathological states.<sup>2</sup> Less well known are the emerging role of this compounds category in the prevention and/or treatment of proliferative diseases, such as cancer. Because cardenolide-like compounds are often quite toxic, however, the potential use of such compounds for the treatment of cancer was abandoned 40 years ago. Even so, studies have revealed that some cardiac glycosides can selectively inhibit human tumor cell growth, but not normal cellular proliferation through complex cell signal transduction mechanisms.<sup>1</sup> Specifically, cardiac glycosides can inhibit growth of cancer cells, induce apoptosis via activation of caspase-3, induce cytochrome C release from mitochondria, and generate reactive oxygen species. In addition, clinical trials of cardiac glycosides and extracts containing them have been initiated to assess the anticancer potential.<sup>2</sup> Therefore, the use of certain cardiac glycosides may represent a worthwhile approach for control of cancer, despite their narrow therapeutic index.

In a previous investigation of bioactive compounds with potential therapeutic value, we reported cardiotoxic principles from *Antiaris toxicaria* (Pers.) Lesch.<sup>3</sup> As a continuation of our anticancer research program based on natural products, an ethanolic extract of *A. toxicaria* (Moraceae) was found to show significant cytotoxicity against KB cells. *A. toxicaria*, also called 'upas tree', is widely distributed in tropical rain forests of Southeast Asia. Phytochemical studies have shown that this plant contains cardiac glycosides,<sup>3,4</sup> prenylaurones,<sup>5</sup> chalcones,<sup>6</sup> flavanones,<sup>6</sup> and dihydrochalcones.<sup>7</sup> Prior investigations also indicated that this species exhibited a broad spectrum of biological activities, such as anti-tumor,<sup>8–12</sup> anti-arrhythmic,<sup>3</sup> and 5-lipoxygenase inhibition effects.<sup>12</sup> Therefore, an intensive investigation of this cytotoxic extract was carried out and led to the isolation of 12 new compounds, together with 53 known compounds. Herein, we describe the isolation, structural elucidation, and antitumor activity of these isolates against ten human cancer cell lines. Preliminary structure–activity relationship (SAR) correlations are also described. In addition, based on the structures of 10-hydroxy-19-nor-cardenolides and 19-nor-cardenolides identified from this plant, a biogenetic pathway of cardiac glycoside has been proposed.

## 2. Results and discussion

Twelve new compounds, including eight cardiac glycosides/ aglycones (**1–8**), two coumarins (**41–42**) and two flavanones (**43–44**) (Fig. 1), together with 53 known compounds, were isolated from an EtOH extract of fresh trunk bark of *A. toxicaria* through column chromatography on silica gel, Diaion HP-20, Sephadex H-20 and semipreparative HPLC. The subfractions were examined by H<sub>2</sub>SO<sub>4</sub> solution spray on TLC for cardiac glycosides, which show as green spots, and subjected to a series of column chromatographic steps in order to obtain cardenolides/aglycones. The structures of new compounds were elucidated on the basis of spectroscopic methods, including 2D NMR techniques.

The HRFAB mass spectrum of **1** showed a molecular ion-related [M+H]<sup>+</sup> peak at *m/z* 567.2808, corresponding to the molecular formula C<sub>29</sub>H<sub>42</sub>O<sub>11</sub>. The NMR signals were due

to one methyl, eleven methylene, eight methine and six quaternary carbons as determined by DEPT 135 spectroscopy (Table 1). Compound **1** showed a UV absorption maximum at 216 nm and IR absorption at 1734  $\text{cm}^{-1}$  ( $\gamma$ -lactone carbonyl), which were indicative of a butenolactone system.<sup>13</sup> The  $^1\text{H}$  NMR spectrum of **1** (Table 2) showed characteristic signals for a butenolactone ring at  $\delta_{\text{H}}$  4.98 and 5.27 (each 1H, d,  $J = 18.1$  Hz, H-21a, and b) and 6.08 (s, H-22), as well as a methyl singlet at  $\delta_{\text{H}}$  0.98 (s, H-18), suggesting **1** to be a cardenolide with a C-18 methyl group. A strong carbonyl absorption in the IR spectrum at 1734  $\text{cm}^{-1}$  and a carbon signal at  $\delta_{\text{C}}$  176.7 in the  $^{13}\text{C}$  NMR spectrum suggested that a carboxylic acid was present at C-19. Comparison of the  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of **1** with those of antiarroside R (**9**),<sup>4</sup> which was isolated from the *n*-BuOH soluble fraction, showed that the two structures were very similar, except for the differences in glycosidic signals and orientation at C-3. An anomeric proton signal at  $\delta_{\text{H}}$  6.08 (s) in the  $^1\text{H}$  NMR spectrum and signals at  $\delta_{\text{C}}$  99.8, 72.7, 72.8, 74.3, 69.9, and 18.6 in the  $^{13}\text{C}$  NMR spectrum indicated the presence of  $\alpha$ -rhamnose. The  $\alpha$ -orientation of C-3 was deduced from the coupling constant values of H-3 (dddd,  $J = 11.0, 11.0, 5.4, 5.4$  Hz). This assignment was supported by downfield shifts of H-2a, H-3, and H-4a from  $\delta_{\text{H}}$  1.43 (m), 4.37 (br s,  $W_{1/2} = 15.7$  Hz), and 1.67 (d,  $J = 12.7$  Hz) in **9** to  $\delta_{\text{H}}$  2.19 (m), 4.81 (dddd,  $J = 11.0, 11.0, 5.4, 5.4$  Hz), and 2.19 (m) in **1**. HMBC correlation of H-1' with C-3 [ $\delta_{\text{C}}$  72.9/ $\delta_{\text{H}}$  6.08 (s)] inferred that the rhamnose unit was linked to C-3. Hence, the structure shown was established for **1** (antiaritoxioside A).

A molecular formula of  $\text{C}_{28}\text{H}_{42}\text{O}_{10}$  was deduced for compound **2**, 12 mass units less than that of periplorhamnoside (**11**).<sup>14</sup> The  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of the two compounds were similar except for the C-19 and C-10 signals. The carbon signal at  $\delta_{\text{C}}$  17.2 (C-19) in **11** was absent in **2**. Furthermore, the carbon signal at  $\delta_{\text{C}}$  41.2 (C-10) in **11** was present at  $\delta_{\text{C}}$  74.4 (C-10) in **2**. Thus, both the NMR and MS data were indicative of a hydroxy rather than methyl group at C-10 in **2**. The  $\beta$ -orientation of the C-3 monosaccharide unit was deduced from the  $W_{1/2}$  constant of H-3 (br s,  $W_{1/2} = 6.6$  Hz). Therefore, the structure of **2** was determined as demethyl-10-hydroxy-periplorhamnoside and **2** was named antiaritoxioside B.

Compound **3** showed a pseudo molecular ion peak at  $m/z$  539.2855 in its HRFABMS and had the same molecular formula,  $\text{C}_{28}\text{H}_{42}\text{O}_{10}$ , as toxicarioside M (**10**),<sup>15</sup> which was also isolated from the *n*-BuOH extract of this plant. The UV, IR and NMR data of **3** strongly resembled those of **10**, consistent with a general structure containing a central cardenolide moiety dioxygenated at C-3, and C-5 and a hydroxy group in the 10-position. The sole significant differences were in certain glycosidic signals (Tables 1 and 2). An anomeric proton signal at  $\delta_{\text{H}}$  5.40 (d,  $J = 5.8$  Hz) in the  $^1\text{H}$  NMR spectrum and signals at  $\delta_{\text{C}}$  99.3, 72.2, 73.1, 73.8, 70.8, and 18.8 in the  $^{13}\text{C}$  NMR spectrum indicated the presence of  $\beta$ -allomethylose. An NOE effect from H-1' to H-3 suggested that the allomethylose unit was attached to C-3. These data agreed with the replacement of the antiarosyl unit in **10** by an allomethylosyl unit in **3**. Thus, the structure of **3** was established for antiaritoxioside C.

A molecular formula of  $\text{C}_{28}\text{H}_{43}\text{O}_{11}$  was deduced for compound **4**, 12 mass units less than that of  $\beta$ -antiarin (**34**),<sup>16</sup> isolated from the  $\text{CHCl}_3$  soluble fraction. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of the two compounds were similar except for the absence of a C-19 aldehyde group

and a downfield shift of C-10 from  $\delta_C$  55.0 in **34** to  $\delta_C$  74.7 in **4**. These data suggested that the aldehyde group in **34** was replaced by a hydroxy group in **4**. This conclusion was supported by  $^3J_{CH}$  HMBC correlations from H-1b and H-11b to C-10. The  $\beta$ -orientations of the C-3 and -12 OH groups were deduced from the coupling constants of H-3 ( $\delta_H$  4.27, br. s,  $W_{1/2} = 7.9$  Hz) and H-12 ( $\delta_H$  3.74, br t,  $J = 7.8$  Hz). Thus, **4** was determined as 10-hydroxy-19-nor- $\beta$ -antiarin and named antiaritosioside D.

Compound **5** had the same molecular formula,  $C_{28}H_{43}O_{11}$ , as **4**. The UV, IR and NMR data also strongly resembled those of **4**, consistent with a structure containing a 19-nor-cardenolide moiety tetraoxygenated at C-3, C-5, C-10 and C-12. The sole significant differences occurred in glycosidic signals of the molecules (Tables 1 and 2). The sugar proton signals of **5** indicated the presence of a  $\beta$ -antiarosyl moiety. These data were consistent with the replacement of the rhamnosyl unit in **5** by an antiarosyl unit in **5**. The  $\beta$ -orientations of C-3 and C-12 were deduced by the  $W_{1/2}$  of H-3 (br s, 7.7 Hz) and H-12 coupling constant (br t,  $J = 9.7$  Hz). Thus, the structure of **5** was assigned as shown, and **5** was named antiaritosioside E.

The HRFAB mass spectrum of **6** showed a molecular ion-related  $[M+Na]^+$  peak at  $m/z$  529.2774, corresponding to the molecular formula  $C_{28}H_{42}O_8$ . The  $^1H$  and  $^{13}C$  NMR data (Tables 1 and 2) indicated that **6** was a 19-nor-cardenolide monosaccharide with a hexose sugar unit. Analyses of COSY, HMQC and HMBC spectra indicated that the sugar was  $\alpha$ -rhamnose. Comparison of the  $^1H$  and  $^{13}C$  NMR spectra of **6** with those of malayoside (**29**),<sup>3,16</sup> showed that the two structures were very similar, except for that **6** did not contain the C-19 aldehyde group found in **29** based on the presence of a methine ( $-CH$ ) proton at  $\delta_H$  1.43 (m), upfield shift of C-10 from  $\delta_C$  51.2 to  $\delta_C$  34.0, and absence of CHO signals. Compound **6** was thus assigned to be 19-nor-malayoside and named antiaritosioside F.

Compound **7** ( $C_{29}H_{45}O_{10}$ ) was 16 mass units larger than **11**.<sup>14</sup> The  $^1H/^{13}C$  NMR spectra of **7** and **11** were very similar, except for the sugar moiety signals and one oxygenated carbon in **7**. The spectra of **11** showed a proton signal at  $\delta_H$  2.81 (dd,  $J = 8.9, 5.1$  Hz) and a carbon signal at  $\delta_C$  51.4 (C-17), while in **7**, the former signal was absent and the latter signal was replaced by an oxygenated carbon signal at  $\delta_C$  87.8 (C-17). Thus, an OH group was attached at C-17 in **7**, and this postulate was supported by a downfield shift of C-16 from  $\delta_C$  27.35 in **11** to  $\delta_C$  34.3 in **7**, together with HMBC correlations of H-18 to C-17. An anomeric proton signal at  $\delta_H$  5.39 (d,  $J = 8.1$  Hz) and carbon signals at  $\delta_C$  99.8, 69.6, 73.8, 73.7, 70.0, and 17.3 indicated the presence of an antiarosyl moiety. An NOE effect between H-3 and H-1' placed the antiarosyl unit on C-3, and a  $W_{1/2}$  coupling constant of 9.8 Hz for H-3 indicated  $\alpha$ -orientation. Therefore, the structure **7** was established for antiaritosioside G.

Compound **8** ( $C_{21}H_{36}O_5$ ) had 21 signals in the  $^{13}C$  NMR spectrum corresponding to two methyl, ten methylene, five methine, and four quaternary carbon atoms. The  $^1H$  and  $^{13}C$  NMR spectra of **8** displayed signals characteristic of the steroid skeleton of a cardenolide. However, the absence of typical signals for the olefinic group and carbonyl carbon of the butenolactone ring, suggested that the five-membered lactone in **8** was absent. This hypothesis was confirmed by the presence of a methylene group at  $\delta_C$  65.8/ $\delta_H$  3.89 (1H, dd,  $J = 10.5, 6.1$  Hz) and 4.08 (1H, dd,  $J = 10.5, 7.2$  Hz, H-21) and one methine at  $\delta_C$  71.1/ $\delta_H$

4.36 (1H, dd,  $J = 7.2, 6.1$  Hz, H-20), as well as the absence of any significant UV absorption. In addition to three OH groups on the steroid skeleton (C-3, C-5 and C-14), two OH groups were assigned at C-20 and C-21, based on carbon signals at  $\delta_C$  71.1 and 65.8, respectively. Orientation of the C-3 OH was also determined by the  $W_{1/2}$  of H-3 (br s,  $W_{1/2} = 11.3$  Hz). The above analysis established the structure of **8** as shown. This compound was reported as an intermediate in the synthesis of periplogenin by Peoghenghi et al.<sup>17</sup> It has been isolated from a natural source for the first time and named antiarotoxinin B.

Compound **41** was obtained as colorless syrup, and its molecular formula was determined to be  $C_{15}H_{18}O_6$  on the basis of HREIMS ( $[M]^+$ ,  $m/z$  294.1100). The IR spectrum showed absorption bands at 3400 and 1711  $cm^{-1}$  for a hydroxyl group and  $\alpha, \beta$ -unsaturated lactone, respectively. UV absorptions at 316 and 258 nm,<sup>18</sup> and two AB type system protons at  $\delta_H$  7.94 and 6.32 (each 1H, d,  $J = 9.6$  Hz, H-4 & -3) suggested that **41** was a coumarin derivative.<sup>19</sup> The  $^1H$  NMR spectrum of **41** also showed an aromatic proton at  $\delta_H$  7.06 (1H, s), three hydroxy protons at  $\delta_H$  9.60, 4.39 and 4.23 (each 1H,  $D_2O$  exchangeable), one methoxy group at  $\delta_H$  3.79 (3H, s) and one 2,3-dihydroxyisopentyl group at  $\delta_H$  1.12 and 1.10 (each 3H, s), 3.36 (1H, m), 2.95 (1H, d,  $J = 13.2$  Hz) and 2.39 (1H, dd,  $J = 13.2, 10.4$  Hz). The  $^{13}C$  NMR spectrum of **41** revealed the presence of 15 carbons resonances including two methyl, one methoxy, one methylene, four methine and seven quaternary carbons. Comparison of the  $^1H$  and  $^{13}C$  NMR spectra of **41** with those of skimmian, which was isolated from *Skimmia anquetelia* by Sharma et al.,<sup>20</sup> showed that the two structures were very similar, except for the absence of signals for a sugar and one additional methoxy group ( $\delta_H$  3.79,  $\delta_C$  60.5) in the former. The HMBC spectrum showed correlations of the methoxy group at  $\delta_H$  3.79 with C-7 ( $\delta_C$  149.9) and of H-1' ( $\delta_H$  2.95, and 2.39) with C-5 ( $\delta_C$  119.7), C-6 ( $\delta_C$  131.0) and C-7 ( $\delta_C$  149.9). Therefore, the methoxy group was attached at C-7 and the 2, 3-dihydroxyisopentyl moiety was located at C-6. This assignment was further confirmed by NOE effects between H-4 ( $\delta_H$  7.94) and H-5 ( $\delta_H$  7.06), as well as H-5 and H-1' for **41**. From the above data, new compound **41** was elucidated as 8-hydroxy-7-methoxy-6-[2', 3'-dihydroxyisopentyl]coumarin, and has been designated as anticarin A.

Compound **42**,  $[\alpha]_D^{25} +38.2^\circ$  ( $c$  0.25, MeOH), was isolated as colorless needles. The HRFABMS exhibited a pseudo-molecular ion at  $m/z$  425.1367 for  $[M+H]^+$ , consistent with the molecular formula  $C_{20}H_{24}O_{10}$ . UV absorptions at 326, 302 (sh), 259, 247 and 220 (sh) nm,<sup>18</sup> and IR band at 1709 (OC=O)  $cm^{-1}$ , as well as two AB type protons at  $\delta_H$  7.96 (1H, d,  $J = 9.2$  Hz, H-4) and 6.26 (1H, d,  $J = 9.2$  Hz, H-3) suggested that **42** was a coumarin derivative.<sup>19</sup> In the  $^1H$  NMR spectrum, the presence of two additional AB type protons at  $\delta_H$  7.54 and 6.76 (each 1H, d,  $J = 8.8$  Hz), two vicinal methine protons at  $\delta_H$  4.84 (1H, d,  $J = 2.4$  Hz) and 3.94 (1H, dd,  $J = 4.4, 2.4$  Hz), and two methyl groups at  $\delta_H$  1.27 (6H, s), indicated that **42** was a khellactone glycoside.<sup>21</sup> The signal at  $\delta_H$  4.84 was assigned as H-4' based on its correlations to C-7 ( $\delta_C$  156.6), C-9 ( $\delta_C$  155.0), C-8 ( $\delta_C$  108.6), and C-1'' ( $\delta_C$  103.8) in the HMBC spectrum, whereas the signal at  $\delta_H$  3.94 was assigned as H-3' based on its correlation to C-3' in the HMQC spectrum, as well as long range correlations of two methyl groups ( $\delta_H$  1.27) to C-3' ( $\delta_C$  70.6). An anomeric proton signal at  $\delta_H$  4.71 (1H, d,  $J = 8.0$  Hz, H-1'') in the  $^1H$  NMR spectrum and signals at  $\delta_C$  103.8, 74.0, 76.8, 70.3, 77.3 and 61.5 in the  $^{13}C$  NMR spectrum suggested the presence of  $\beta$ -glucose. The coupling constant



of the anomeric doublet ( $\delta_{\text{H}}$  4.71, 8.0 Hz) suggested a  $\beta$ -glucosidic linkage for the khellactone. The FAB-MS spectrum showed an ion fragment at  $m/z$  263[M<sup>+</sup>-162], also indicating the presence of a hexose moiety. The  $\beta$ -glucose unit was placed at C-4' on the basis of HMBC correlation between H-1'' of the glucose unit and C-4' of the aglycone moiety, together with NOE correlation between H-1'' and H-4'. Accordingly, the structure of **42** was established as 4'- $\beta$ -glucosyl-khellactone, and **42** has been named anticarin B.

Compound **43** was obtained as colorless needles. The molecular formula was established as C<sub>21</sub>H<sub>22</sub>O<sub>6</sub> from  $m/z$  370.1412 [M]<sup>+</sup> in HREIMS. The IR spectrum of **43** showed absorption bands at 3456 and 3175 cm<sup>-1</sup> for one or more hydroxy group(s) and 1638 cm<sup>-1</sup> for a conjugated carbonyl functionality. The presence of a flavanone skeleton was evident from UV [226 (sh), 288, and 328 (sh) nm],<sup>18</sup> and <sup>1</sup>H [ $\delta_{\text{H}}$  2.66 (1H, *dd*,  $J$ =17.2, 2.8 Hz, H-3 $\alpha$ ), 3.16 (1H, *dd*,  $J$ =17.2, 13.2 Hz, H-3 $\beta$ ) and 5.62 (1H, *dd*,  $J$ =13.2, 2.8 Hz, H-2)] and <sup>13</sup>C [ $\delta_{\text{C}}$  79.9 (C-2), 43.1 (C-3) and 197.4 (C-4)] NMR spectra. The <sup>1</sup>H NMR spectrum further showed three hydroxy groups [ $\delta_{\text{H}}$  12.17, 9.69 and 7.55 (each 1H, *s*)], two singlet aromatic protons [ $\delta_{\text{H}}$  5.96 (2H, *s*)], AB system aromatic protons [ $\delta_{\text{H}}$  6.90 (1H, *d*,  $J$ =8.4 Hz) and 7.06 (1H, *d*,  $J$ =8.4 Hz)], a methoxy moiety [ $\delta_{\text{H}}$  3.86 (3H, *s*)], and an isoprenyl group [ $\delta_{\text{H}}$  1.67 (3H, *s*), 1.63 (3H, *s*), 3.52 (2H, *d*,  $J$ =6.4 Hz) and 5.13 (1H, *t*,  $J$ =6.4 Hz)]. The locations of these substituents were determined by HMQC and HMBC experiments. Based on <sup>3</sup>*J*-correlations between the proton at  $\delta_{\text{H}}$  5.96 with C-5 ( $\delta_{\text{C}}$  165.1), C-7 ( $\delta_{\text{C}}$  167.2), and C-10 ( $\delta_{\text{C}}$  103.0) in the HMBC experiment and with C-6 in a HMQC spectrum, the singlet aromatic protons were assigned to H-6 and H-8, respectively, of ring-A HMBC correlations of the proton at  $\delta_{\text{H}}$  6.90 to C-1' ( $\delta_{\text{C}}$  130.5) and C-3' ( $\delta_{\text{C}}$  144.8) and at  $\delta_{\text{H}}$  7.06 to C-2 ( $\delta_{\text{C}}$  79.9) and C-2' ( $\delta_{\text{C}}$  126.9) suggested that the AB system aromatic protons belonged H-5' and H-6', respectively. Combined with HMBC correlations of H-1'' ( $\delta_{\text{H}}$  3.52) to C-1' ( $\delta_{\text{C}}$  130.5), C-2' ( $\delta_{\text{C}}$  126.9), C-3' ( $\delta_{\text{C}}$  144.8), and C-2'' ( $\delta_{\text{C}}$  124.0), and methoxy protons ( $\delta_{\text{H}}$  3.86) to C-4' ( $\delta_{\text{C}}$  148.0) implied that the isoprenyl group was attached to C-2', while the methoxy group was located at C-4'. These assignments were further confirmed by an NOE effect between the methoxy group and H-5' ( $\delta_{\text{H}}$  6.90). Finally, a hydroxy group was attached to C-3'. The *S*-configuration of C-2 was determined by a positive Cotton effect observed at 312 nm and a negative one at 286 nm in the circular dichroism (CD) spectrum of **43**.<sup>22</sup> Based on these observations, **43** was established as (2*S*)-3',5,8-trihydroxy-4'-methoxy-6,7-methylenedioxy-2'-prenylflavanone, and named antiarone L.

The molecular formula of **44** was determined as C<sub>25</sub>H<sub>26</sub>O<sub>6</sub> from a molecular ion peak at  $m/z$  423.1733 [M+H]<sup>+</sup> in its HRESIMS. The UV (324, 286, and 231 nm),<sup>18</sup> <sup>1</sup>H, and <sup>13</sup>C NMR spectra indicated that **44** was also a flavanone. The <sup>1</sup>H and <sup>13</sup>C NMR spectra of **44** closely resembled those of **43** except that signals for a 2,2-dimethylpyran ring unit were present at  $\delta_{\text{H}}$  6.40 (1H, *d*,  $J$ =9.8 Hz, H-4'''), 5.73 (1H, *d*,  $J$ =9.8 Hz, H-3'''), 1.20 and 1.18 (6H, *s*, 2'''-CH<sub>3</sub>) and  $\delta_{\text{C}}$  122.7 (C-4'''), 131.3 (C-3'''), 77.5 (C-2'''), 29.1 & 32.4 (2'''-CH<sub>3</sub>) in **44**, and the methoxy group found in **43** was absent. Correlations of H-1'' [ $\delta_{\text{H}}$  3.48 (2H, *d*,  $J$ =6.8 Hz)] to C-1' ( $\delta_{\text{C}}$  130.1), C-2' ( $\delta_{\text{C}}$  124.0) and C-3' ( $\delta_{\text{C}}$  143.8) in the HMBC spectrum indicated an isoprenyl group was attached to C-2', whereas long range correlations of H-4''' ( $\delta_{\text{H}}$  6.40) to C-4' ( $\delta_{\text{C}}$  140.5), C-5' ( $\delta_{\text{C}}$  133.1) and C-6' ( $\delta_{\text{C}}$  120.0) and of H-3''' ( $\delta_{\text{H}}$  5.73) to C-5'

suggested that the 2,2-dimethylpyran ring was fused to C-5' and 4'. The absolute stereochemistry of **44** was deduced to be 2S because of a positive Cotton effect at 314 nm and a negative one at 290 nm in the circular dichroism (CD) spectrum of **44**.<sup>22</sup> Thus, the structure of compound **44** was assigned as (2S)-2''',2'''-dimethylpyrano-3',5,8-trihydroxy-2'-prenylflavanone, and named antiarone K.

Antiaroside R (**9**),<sup>4</sup> toxicarioside M (**10**),<sup>15</sup> periplorhamnoside (**11**),<sup>14</sup> antiaroside A (**12**),<sup>3</sup> peripalloside (**13**),<sup>14</sup> cheiranthoside (**14**),<sup>23</sup> strophanthidol (**15**),<sup>24</sup> convallatoxal (**16**),<sup>16</sup> cannogenol (**17**),<sup>25</sup> antiaroside B (**18**),<sup>3</sup> strophanthidin (**19**),<sup>14</sup> convallatoxin (**20**),<sup>16</sup> strophathojavoside (**21**),<sup>26</sup> desglucocheirototoxin (**22**),<sup>24</sup> strophalloside (**23**),<sup>14</sup> convalloside (**24**),<sup>27</sup> glucostraphalloside (**25**),<sup>28</sup> cheirototoxin (**26**),<sup>29</sup> antiaroside C (**27**),<sup>3</sup> antiaroside D (**28**),<sup>3</sup> malayoside (**29**),<sup>3,16</sup> antiarigenin (**30**),<sup>14</sup>  $\alpha$ -antiarin (**31**),<sup>16</sup> antialloside (**32**),<sup>26</sup> toxicarioside B (**33**),<sup>30</sup>  $\beta$ -antiarin (**34**),<sup>16</sup> antiaroside E (**35**),<sup>3</sup> antiaroside F (**36**),<sup>3</sup> antiaroside G (**37**),<sup>3</sup> antiaroside H (**38**),<sup>3</sup> antiaroside I (**39**),<sup>3</sup> antiarototoxinin A (**40**),<sup>3</sup> (+)-marmesin (**45**),<sup>31</sup> decursinol (**46**),<sup>21</sup> (*R*)-peucedanol (**47**),<sup>32</sup> oxypeucedanin hydrate (**48**),<sup>33</sup> (2S)-pinocembrin (**49**),<sup>34</sup> antiarones F (**50**),<sup>6</sup> I (**51**),<sup>6</sup> vanillic acid (**52**),<sup>35</sup> *p*-hydroxybenzoic acid (**53**),<sup>36</sup> vanillin (**54**),<sup>35</sup> (3*S*,4*R*)-hydroxymellein (**55**),<sup>37</sup> 2, 4,6-trihydroxy-5-methoxyacetophenone (**56**),<sup>38</sup> 6-acetoxy-2,4-dihydroxyacetophenone (**57**),<sup>39</sup> syringic acid (**58**),<sup>40</sup> koaburaside (**59**),<sup>41</sup> vanilloyl  $\beta$ -D-glucose (**60**),<sup>42</sup> uridine (**61**),<sup>43</sup> xanthine (**62**),<sup>44</sup> adenosine (**63**),<sup>36</sup> 3-hydroxy-5-methoxybenzalacetophenone (**64**),<sup>45</sup> and  $\beta$ -sitosterol (**65**)<sup>35</sup> were also isolated and identified by comparison of their physical and spectroscopic properties with those reported in the literature.

Cardenolides **11–40** and coumarins **41**, **42**, and **45** were assayed for anti-proliferative effects against 10 human cancer cell lines, KB, KB-VIN, A549, MCF-7, U-87-MG, PC-3, 1A9, CAKI-1, HCT-9, and S-KMEL-2.<sup>46</sup> The cytotoxic data are shown in Table 3. Among the tested isolates, compounds **11**, **12**, **16**, **17**, **19–25**, **29**, **31–35**, and **42** exhibited potent effects against all cancer cell lines. Among them, compounds **12**, **16**, **20**, **22**, and **31** showed ng/mL potency against one or more cancer cell lines. Compound **12** exhibited an ED<sub>50</sub> of 0.0097  $\mu$ g/mL against KB cancer cell lines. Compound **16** demonstrated ED<sub>50</sub> values of 0.0040, 0.0076, and 0.0061  $\mu$ g/mL against A549, 1A9 and CAKI-1 cells, respectively. Compound **20** showed ED<sub>50</sub> values of 0.0027, 0.0065, 0.0031, 0.0014 and 0.0013  $\mu$ g/mL against A549, MCF-7, CAKI-1, HCT-9 and s-KMEL-2 cells, respectively. Compound **22** exhibited an ED<sub>50</sub> of 0.0092  $\mu$ g/mL against A549 cells. Finally, compound **31** showed an ED<sub>50</sub> of 0.0044  $\mu$ g/mL against PC-3 cells. Common structural features in all five compounds included a 5 $\beta$ -OH, 13 $\beta$ -Me, 14 $\beta$ -OH, and 17 $\beta$ - $\alpha$ ,  $\beta$ -unsaturated- $\gamma$ -butyrolactone. Compounds **20**, **22**, and **31** contained a C-18  $\beta$ -CHO, while **12** and **16** contained  $\beta$ -CH<sub>3</sub> and -CH<sub>2</sub>OH, respectively. Compound **31** contained a C-12  $\beta$ -OH, while compounds **12**, **16**, **20**, and **22** were unsubstituted. All five compounds contained a 3 $\beta$ -sugar moiety, 3 $\beta$ -O- $\beta$ -D-antiarose in **12**, **22**, and **31**, 3 $\beta$ -O- $\alpha$ -L-rhamnose in **16** and **20**.

The following specific structure-activity correlations were noted in these studies. Changing the orientation of the glycoside from 3 $\beta$  in potent cardenolide **20** to 3 $\alpha$  in **27** significantly decreased the cytotoxicity, for example, from 0.0027 to 0.48  $\mu$ g/mL against A549, from 0.0065 to 1.4 against MCF-7, from 0.0031 to 0.31  $\mu$ g/mL against CAKI-1, from 0.0014 to

1.5  $\mu\text{g}/\text{mL}$  against HCT-9, and from 0.0013 to 0.26  $\mu\text{g}/\text{mL}$  against s-KMEL-2. Compound **28** with a 3 $\alpha$ -diglycoside was also one of the least potent cardenolides. Activity decreased dramatically when the 3 $\beta$ -O- $\alpha$ -L-rhamnose of **16** ( $\text{ED}_{50}$  values 0.0040–0.036  $\mu\text{g}/\text{mL}$ ) was changed to 3 $\beta$ -OH in **15** ( $\text{ED}_{50}$  values 0.14–6.5  $\mu\text{g}/\text{mL}$ ). Replacement of the C-10  $\text{CH}_3$  of **12** with COOH in **38** together with addition of a 12 $\beta$ -OH decreased cytotoxicity from 0.0097 to 5.9  $\mu\text{g}/\text{mL}$  against KB cells. Similarly, changing the C-10  $\text{CH}_2\text{OH}$  of **16** to H in **39** decreased cytotoxicity from 0.0040 to 0.36  $\mu\text{g}/\text{mL}$  against A549 cells. Compounds showing the lowest potency against the cancer cell lines included **14**, **15**, **27**, and **28** with  $\text{ED}_{50}$  values ranging from 0.12 to 4.2  $\mu\text{g}/\text{mL}$ , as well as **30** and **36–40** with  $\text{ED}_{50}$  values of 0.36–17.5  $\mu\text{g}/\text{mL}$ . Notably, a C-10 COOH, COO-glucose, or H was found in **36–39** rather than CHO,  $\text{CH}_3$ , or  $\text{CH}_2\text{OH}$  as found in the more potent compounds. While the cytotoxic effects of new compounds **1–6** were not examined in this report,<sup>46</sup> the cytotoxic effects of structurally similar cardiac glycosides have been reported.<sup>4,10</sup> Our observations were generally consistent with the prior findings (for example, compound **9** with COO-glucose at C-10 and compounds with  $\alpha$ -oriented substituents at C-3 exhibited lower cytotoxicity).<sup>4</sup> In summary, from our investigation, the  $\beta$ -orientation of C-3, C-3 monosaccharide, and C-10 substituents (CHO,  $\text{CH}_3$ , or  $\text{CH}_2\text{OH}$ ) are crucial factors in the cytotoxicity effects of cardiac glycosides. Prior reports also indicated that compounds with C-10 OH may exhibit significant cytotoxicity.<sup>10</sup>

Among the three tested coumarins, compound **41** and the structurally related linear dihydrofuranocoumarin **45** showed no cytotoxic activity, whereas the angular dihydropyranocoumarin **42** exhibited broad and significant cytotoxicity against KB-VIN, A549, MCF-7, PC-3, 1A9, CAKI-1 and S-KMEL-2 cell lines with  $\text{ED}_{50}$  values ranging from 1.2 to 4.1  $\mu\text{g}/\text{mL}$ .

It is a definite possibility that the structurally similar cardiac glycoside metabolites were derived biogenetically from a general catabolic process. A possible biogenetic transformation pathway is presented in Scheme 1 for the first time on the basis of evidence from natural sources. The proposed biosynthesis could explain the catabolic progression of structurally interesting cardiac glycosides.

### 3. Conclusions

In summary, this paper described the isolation and structure elucidation of 12 new compounds, including eight cardiac glycosides/aglycones, antiarotoxiosides A-G (**1–7**) and antiarotoxinin B (**8**), two coumarins, anticarin A–B, and two flavanones, antiarones L–K. The cytotoxic activity of cardiac glycosides and coumarins against ten cancer cell lines also reported. Compounds **12**, **16**, **20**, **22**, and **31** showed significant cytotoxicity against all 10 cancer cell lines, with notable potency at the ng/mL level against some cell lines. SAR correlations were also identified. While many cardiac glycosides are reported in the literature, compounds with 10-carboxy (e.g., **1**, **9**) and 3 $\alpha$ -hydroxy (e.g., **1**) substituents are rare. Furthermore, the C-10 substituents, including COOH, CHO,  $\text{CH}_2\text{OH}$ ,  $\text{CH}_3$ , OH and H, of cardiac glycosides can help to explain the catabolic progression of structurally interesting cardiac glycosides.



## 4. Experimental

### 4.1. General procedures

Optical rotations were measured with a JASCO DIP-370 polarimeter. IR spectra were determined as KBr discs on a Shimadzu FTIR-8501 spectrophotometer. UV spectra were acquired on a Hitachi UV-3210 spectrophotometer. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on Bruker Avance 300 ( $^1\text{H}$  at 300 MHz) and AMX 400 ( $^1\text{H}$  at 400 MHz) spectrometers. The  $^1\text{H}$  and  $^{13}\text{C}$  chemical shifts (ppm) were referenced to the solvent peaks for pyridine- $d_5$  at  $\delta_{\text{H}}$  8.71 and  $\delta_{\text{C}}$  149.9, DMSO- $d_6$  at  $\delta_{\text{H}}$  2.49 and  $\delta_{\text{C}}$  39.5, acetone- $d_6$  at  $\delta_{\text{H}}$  2.05 and  $\delta_{\text{C}}$  29.9, 206.7, and methanol- $d_4$  at  $\delta_{\text{H}}$  3.31 and  $\delta_{\text{C}}$  49.0. ESIMS, FABMS and HRMS were taken with a VG 70–250 S spectrometer by direct inlet system. Merck silica gel 60 (Merck 70–230, 230–400 mesh) was used for column chromatography. Glass sheets of silica gel 60 F<sub>254</sub> (Merck 0.2 mm thick) were used for TLC. Melting points were measured on a Yanagimoto MP-S3 micromelting point apparatus and are uncorrected.

### 4.2. Plant material

Trunk bark of *A toxicaria* was collected from Yunnan, China, and authenticated by C.S. Kuoh (Department of Life Sciences, National Cheng Kung University, Tainan, Taiwan). A voucher specimen (NCKUWu 92012) has been deposited in the Herbarium of National Cheng Kung University, Tainan, Taiwan, R.O.C.

### 4.3. Extraction and isolation

Trunk bark of *A toxicaria* (6.0 kg) was cut into small pieces and extracted with 95% EtOH (20 L  $\times$  3). Evaporation of the solvent under reduced pressure provided 239.0 g of crude extract, which was partitioned between  $\text{CHCl}_3$ – $\text{H}_2\text{O}$ , and *n*-BuOH– $\text{H}_2\text{O}$ , successively, to yield  $\text{CHCl}_3$  (AT-C, 65.1 g), *n*-BuOH (AT-B, 100.2 g), and  $\text{H}_2\text{O}$  (AT-W, 73.7 g) fractions. The  $\text{CHCl}_3$  fraction was subjected to silica gel CC using increasing polarity mixtures of *n*-hexanes-acetone as eluant to give 14 fractions (AT-C-1 ~ 14). AT-C-2 was recrystallized to obtain **65** (42.5 mg). AT-C-3 was chromatographed on silica gel using *n*-hexane–diisopropyl ether (3:1) to obtain **56** (1.2 mg), **57** (1.7 mg), and **64** (11.5 mg). AT-C-4 was chromatographed on silica gel using *n*-hexane–diisopropyl ether (3:1) to obtain **43** (12.4 mg), **49** (3.1 mg), **50** (10.0 mg), **51** (175.4 mg), **55** (1.2 mg), and **64** (2.4 mg). AT-C-5 was chromatographed on silica gel eluted with *n*-hexane–diisopropyl ether (1:1) to give **43** (18.0 mg), **44** (1.0 mg), **49** (3.7 mg), **50** (17.1 mg), and **55** (2.4 mg). AT-C-6 was chromatographed on silica gel using diisopropyl ether–MeOH (40:1) to obtain **7** (8.7 mg), **19** (103.2 mg), **46** (3.1 mg), **52** (8.7 mg), **54** (12.3 mg), and **65** (12.5 mg). AT-C-7 was chromatographed on silica gel and eluted with *n*-hexane–diisopropyl ether (1:1) to give **15** (6.6 mg) and **21** (7.0 mg). AT-C-8 was chromatographed on silica gel using EtOAc–MeOH (20:1) to obtain **6** (2.1 mg), **8** (19.6 mg), **17** (3.2 mg), **29** (8.8 mg), **35** (37.6 mg), and **39** (7.5 mg). AT-C-9 and 10 were chromatographed on silica gel using EtOAc–MeOH (20:1) to obtain **29** (21.4 mg), and **20** (117.2 mg), respectively.

The *n*-BuOH fraction was subjected to Diaion HP-20 CC eluting with a  $\text{H}_2\text{O}$ –MeOH gradient system to give 12 fractions (AT-B-1 ~ 12). AT-B-4 and 5 were chromatographed on silica gel using  $\text{CHCl}_3$ –MeOH (9:1) to obtain **4** (1.3 mg), **5** (1.5 mg), **30** (58.9 mg), **31**

(11.0 mg), **32** (4.3 mg), **34** (7.3 mg), **37** (34.7 mg), **38** (147.4 mg), **52** (10.0 mg), **53** (10.2 mg), and **54** (5.5 mg), successively. AT-B-6 was chromatographed on silica gel using  $\text{CHCl}_3$ –MeOH (9:1) to obtain **31** (118.4 mg). AT-B-7 and 8 were chromatographed on silica gel using  $\text{CHCl}_3$ –MeOH– $\text{H}_2\text{O}$  (9:1:0.005) to obtain **1** (3.0 mg), **2** (3.8 mg), **10** (0.5 mg), **14** (9.1 mg), **16** (6.1 mg), **18** (12.3 mg), **20** (431.2 mg), **22** (4.3 mg), **23** (5.9 mg), **24** (91.2 mg), **25** (18.3 mg), **26** (0.5 mg), **27** (112.3 mg), **28** (12.2 mg), **36** (5.9 mg), **41** (25.3 mg), **42** (5.8 mg), **47** (6.7 mg), and **58** (2.7 mg), successively. AT-B-9 and 10 were chromatographed on silica gel using  $\text{CHCl}_3$ –MeOH– $\text{H}_2\text{O}$  (9:1:0.05) to obtain **3** (0.3 mg), **11** (10.9 mg), **12** (9.8 mg), **13** (1.9 mg), **20** (12.5 mg), **22** (29.9 mg), **23** (17.8 mg), **33** (13.5 mg), **40** (0.7 mg), **45** (1.2 mg), **48** (0.9 mg), and **53** (2.8 mg), successfully.

The  $\text{H}_2\text{O}$  fraction was subjected to Diaion HP-20 CC eluting with a  $\text{H}_2\text{O}$ –MeOH gradient system to give 10 fractions (AT-W-1 ~ 10). AT-W-2 and 3 were chromatographed on silica gel using EtOAc–MeOH– $\text{H}_2\text{O}$  (4:1:0.5) to obtain **61** (2.3 mg), and **62** (10.7 mg). AT-W-4 was chromatographed on silica gel using EtOAc–MeOH– $\text{H}_2\text{O}$  (4:1:0.5) to obtain **59** (22.4 mg), **60** (29.0 mg), and **63** (1.2 mg). AT-W-5 was chromatographed on silica gel using  $\text{CHCl}_3$ –MeOH– $\text{H}_2\text{O}$  (4:1:0.005) to obtain **59** (12.6 mg). AT-W-6 and 7 was chromatographed on silica gel using EtOAc–MeOH– $\text{H}_2\text{O}$  (4:1:0.5) to obtain **58** (17.3 mg). AT-W-8 and 9 were chromatographed on Sephadex LH-20 using a  $\text{H}_2\text{O}$ –MeOH gradient system to obtain **9** (0.7 mg), **20** (43.2 mg), **24** (26.8 mg), **28** (26.4 mg), **31** (20.2 mg) and **32** (1.3 mg), successfully.

#### 4.4. Antiaritoxioside A (1)

Colorless syrup;  $[\alpha]_{\text{D}}^{25} +189.13^\circ$  (*c* 0.01 in MeOH); UV  $\lambda_{\text{max}}$  (MeOH)/nm (log  $\epsilon$ ) 216 (4.21); IR  $\nu_{\text{max}}/\text{cm}^{-1}$  (KBr) 3400, 2930, 1734, 1651, 1506, 1456, 1394, 1229, 1026;  $^1\text{H}$  NMR data (pyridine- $d_5$ ) see Table 2;  $^{13}\text{C}$  NMR data (pyridine- $d_5$ ) see Table 1; FABMS  $m/z$  567 (13%)  $[\text{M}+\text{H}]^+$ ; HRFABMS  $m/z$  567.2808 ( $\text{C}_{29}\text{H}_{43}\text{O}_{11}$   $[\text{M}+\text{H}]^+$  requires 567.2805).

#### 4.5. Antiaritoxioside B (2)

Colorless syrup;  $[\alpha]_{\text{D}}^{25} -9.52^\circ$  (*c* 0.04 in MeOH); UV  $\lambda_{\text{max}}$ (MeOH)/nm (log  $\epsilon$ ) 215 (4.31); IR  $\nu_{\text{max}}/\text{cm}^{-1}$  (KBr) 3440, 2937, 1744, 1647, 1634, 1454, 1032;  $^1\text{H}$  NMR data (pyridine- $d_5$ ) see Table 2;  $^{13}\text{C}$  NMR data (pyridine- $d_5$ ) see Table 1; FABMS  $m/z$  539 (8%)  $[\text{M}+\text{H}]^+$ ; HRFABMS  $m/z$  539.2855 ( $\text{C}_{28}\text{H}_{43}\text{O}_{10}$   $[\text{M}+\text{H}]^+$  requires 539.285).

#### 4.6. Antiaritoxioside C (3)

Colorless syrup;  $[\alpha]_{\text{D}}^{25} -242.2^\circ$  (*c* 0.003 in MeOH); UV  $\lambda_{\text{max}}$  (MeOH)/nm (log  $\epsilon$ ) 213 (4.14); IR  $\nu_{\text{max}}/\text{cm}^{-1}$  (KBr) 3410, 2928, 1734, 1647, 1636, 1541, 1456, 1076, 1036;  $^1\text{H}$  NMR data (pyridine- $d_5$ ) see Table 2;  $^{13}\text{C}$  NMR data (pyridine- $d_5$ ) see Table 1; FABMS  $m/z$  539 (6%)  $[\text{M}+\text{H}]^+$ ; HRFABMS  $m/z$  539.2855 ( $\text{C}_{28}\text{H}_{43}\text{O}_{10}$   $[\text{M}+\text{H}]^+$  requires 539.2856).

#### 4.7. Antiaritoxioside D (4)

Colorless syrup;  $[\alpha]_{\text{D}}^{25} -45.88^\circ$  (*c* 0.01 in MeOH); UV  $\lambda_{\text{max}}$  (MeOH)/nm (log  $\epsilon$ ) 214 (4.17); IR  $\nu_{\text{max}}/\text{cm}^{-1}$  (KBr) 3410, 2932, 1742, 1649, 1454, 1377, 1029;  $^1\text{H}$  NMR data (pyridine- $d_5$ )

see Table 2;  $^{13}\text{C}$  NMR data (pyridine- $d_5$ ) see Table 1; FABMS  $m/z$  555 (3%)  $[\text{M}+\text{H}]^+$ ; HRFABMS  $m/z$  555.2805 ( $\text{C}_{28}\text{H}_{43}\text{O}_{11}$   $[\text{M}+\text{H}]^+$  requires 555.2805).

#### 4.8. Antiaritoxioside E (5)

Colorless syrup;  $[\alpha]_{\text{D}}^{25} -69.72^\circ$  ( $c$  0.02 in MeOH); UV  $\lambda_{\text{max}}$  (MeOH)/nm ( $\log \epsilon$ ) 271 (3.63), 218 (4.36); IR  $\nu_{\text{max}}/\text{cm}^{-1}$  (KBr) 3410, 2945, 1732, 1640, 1630, 1452, 1385, 1171, 1109, 1078, 1028, 997;  $^1\text{H}$  NMR data (pyridine- $d_5$ ) see Table 2;  $^{13}\text{C}$  NMR data (pyridine- $d_5$ ) see Table 1; FABMS  $m/z$  555 (8%)  $[\text{M}+\text{H}]^+$ ; HRFABMS  $m/z$  555.2802 ( $\text{C}_{28}\text{H}_{43}\text{O}_{11}$   $[\text{M}+\text{H}]^+$  requires 555.2805).

#### 4.9. Antiaritoxioside F (6)

Colorless syrup;  $[\alpha]_{\text{D}}^{25} -15.28^\circ$  ( $c$  0.02 in MeOH); UV  $\lambda_{\text{max}}$  (MeOH)/nm ( $\log \epsilon$ ) 216 (4.32); IR  $\nu_{\text{max}}/\text{cm}^{-1}$  (KBr) 3410, 2926, 1742, 1645, 14474, 1377, 1049;  $^1\text{H}$  NMR data (pyridine- $d_5$ ) see Table 2;  $^{13}\text{C}$  NMR data (pyridine- $d_5$ ) see Table 1; FABMS  $m/z$  529 (7%)  $[\text{M}+\text{Na}]^+$ , 507 (5%)  $[\text{M}+\text{H}]^+$ ; HRFABMS  $m/z$  529.2774 ( $\text{C}_{28}\text{H}_{42}\text{-NaO}_8$   $[\text{M}+\text{Na}]^+$  requires 529.2777).

#### 4.10. Antiaritoxioside G (7)

Colorless powder ( $\text{CHCl}_3$ -MeOH); mp 227–228 °C;  $[\alpha]_{\text{D}}^{25} -57.69^\circ$  ( $c$  0.01 in MeOH); UV  $\lambda_{\text{max}}$  (MeOH)/nm ( $\log \epsilon$ ) 215 (4.62); IR  $\nu_{\text{max}}/\text{cm}^{-1}$  (KBr) 3350, 2949, 1753, 1383, 1286, 1175, 1101, 1022, 991;  $^1\text{H}$  NMR data (pyridine- $d_5$ ) see Table 2;  $^{13}\text{C}$  NMR data (pyridine- $d_5$ ) see Table 1; FABMS  $m/z$  553 (2%)  $[\text{M}+\text{H}]^+$ ; HRFABMS  $m/z$  553.3014 ( $\text{C}_{29}\text{H}_{45}\text{O}_{10}$   $[\text{M}+\text{H}]^+$  requires 553.3012).

#### 4.11. Antiarotoxinin B (8)

Colorless powder ( $\text{CHCl}_3$ -MeOH); mp >280 °C;  $[\alpha]_{\text{D}}^{25} -31.34^\circ$  ( $c$  0.02 in MeOH); IR  $\nu_{\text{max}}/\text{cm}^{-1}$  (KBr) 3261, 2936, 2882, 1470, 1448, 1383, 1088, 1047;  $^1\text{H}$  NMR data (pyridine- $d_5$ ) see Table 2;  $^{13}\text{C}$  NMR data (pyridine- $d_5$ ) see Table 1; EIMS  $m/z$  368 (8%)  $[\text{M}]^+$ , 350 (28%), 319 (39%), 301 (41%), 296 (100%), 290 (15%), 283 (20%), 272 (14%), 147 (12%), 121 (15%), 107 (28%), 97 (39%); HREIMS  $m/z$  368.2560 ( $\text{C}_{21}\text{H}_{36}\text{O}_5$   $[\text{M}]^+$  requires 368.2563).

#### 4.12. Anticarin A (41)

Colorless syrup;  $[\alpha]_{\text{D}}^{25} +16.3^\circ$  ( $c$  0.058, MeOH); UV  $\lambda_{\text{max}}$  (MeOH)/nm ( $\log \epsilon$ ) 316 (3.60), 258 (3.48); IR  $\nu_{\text{max}}/\text{cm}^{-1}$  (KBr) 3400, 2926, 1711, 1607, 1572, 1450, 1279;  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta_{\text{H}}$  9.60 (1H, br s,  $\text{D}_2\text{O}$  exchangeable, OH), 7.94 (1H, d,  $J = 9.6$  Hz, H-4), 7.06 (1H, s, H-5), 6.32 (1H, d,  $J = 9.6$  Hz, H-3), 4.39 (1H, d,  $J = 6.0$  Hz,  $\text{D}_2\text{O}$  exchangeable, 2'-OH), 4.23 (1H, br s,  $\text{D}_2\text{O}$  exchangeable, 3'-OH), 3.79 (3H, s,  $\text{OCH}_3$ ), 3.36 (1H, m, H-2'), 2.95 (1H, d,  $J = 13.2$  Hz, H-1'), 2.39 (1H, dd,  $J = 13.2, 10.4$  Hz, H-1'), 1.12 (3H, s, H-4'), 1.10 (3H, s, H-5');  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta_{\text{C}}$  160.3 (C-2), 149.9 (C-7), 145.0 (C-4), 142.3 (C-9), 137.2 (C-8), 131.0 (C-6), 119.7 (C-5), 115.0 (C-10), 114.0 (C-3), 77.8 (C-2'), 71.9 (C-3'), 60.5 ( $\text{OCH}_3$ ), 31.4 (C-1'), 26.6 (C-5'), 24.8 (C-4'); EIMS  $m/z$  294 (28%)  $[\text{M}]^+$ , 261 (7%), 236 (79%), 235 (37%), 221 (23%), 205 (100%), 193 (56%), 177 (20%),

163 (25%), 147 (22%), 59 (84%); HREIMS  $m/z$  294.1100 ( $C_{15}H_{18}O_6$   $[M]^+$  requires 294.1103).

#### 4.13. Anticarin B (42)

Colorless needles (MeOH); mp. 265–267 °C;  $[\alpha]_D^{25} +38.2^\circ$  ( $c$  0.2523, MeOH); UV  $\lambda_{max}$  (MeOH)/nm (log  $\epsilon$ ) 326 (4.18), 302 (3.92, sh), 259 (3.46), 247 (3.50), 220(4.13, sh), 204 (4.67); IR  $\nu_{max}/cm^{-1}$  (KBr) 3300, 1709, 1605, 1592, 1541, 1306, 1126, 1076, 1036;  $^1H$  NMR (400 MHz, DMSO- $d_6$ )  $\delta_H$  7.96 (1H, d,  $J$  = 9.2 Hz, H-4), 7.54 (1H, d,  $J$  = 8.8 Hz, H-5), 6.76 (1H, d,  $J$  = 8.8 Hz, H-6), 6.26 (1H, d,  $J$  = 9.2 Hz, H-3), 5.29 (1H, d,  $J$  = 4.4 Hz, D<sub>2</sub>O exchangeable, 3'-OH), 4.93 (2H, m, D<sub>2</sub>O exchangeable, 3'', 4''-OH), 4.84 (1H, br. d,  $J$  = 2.4 Hz, H-4'), 4.71 (1H, d,  $J$  = 8.0 Hz, H-1''), 4.52 (1H, br s, D<sub>2</sub>O exchangeable, 4'-OH), 4.42 (1H, t,  $J$  = 6.0 Hz, D<sub>2</sub>O exchangeable, 6''-OH), 3.94 (1H, dd,  $J$  = 4.4, 2.4 Hz, H-3'), 3.76 (1H, br. dd,  $J$  = 12.0, 6.0 Hz, H-6''), 3.50 (1H, br s dd,  $J$  = 12.0, 6.0 Hz, H-6''), 3.25 (1H, m, H-5''), 3.22 (1H, t,  $J$  = 8.4 Hz, H-3''), 3.05 (1H, m, H-4''), 2.90 (1H, t,  $J$  = 8.4 Hz, H-2''), 1.27 (6H, s, 20-CH<sub>3</sub> × 2);  $^{13}C$  NMR (100 MHz, DMSO- $d_6$ )  $\delta_C$  160.1 (C-2), 156.6 (C-7), 155.0 (C-9), 144.8 (C-4), 129.1 (C-5), 114.1 (C-6), 112.0 (C-3, 10), 108.6 (C-8), 103.8 (C-1''), 78.5 (C-2'), 77.3 (C-5''), 76.8 (C-3''), 74.0 (C-2''), 71.4 (C-4'), 70.6 (C-3'), 70.3 (C-4''), 61.5 (C-6''), 24.9 & 24.3 (2'-CH<sub>3</sub> × 2); FABMS  $m/z$  425 (23%)  $[M+H]^+$ , 371 (8%), 307 (10%), 263 (75%), 245 (31%), 219 (74%), 154 (100%), 136 (86%); HRFABMS  $m/z$  425.1367 ( $C_{20}H_{25}O_{10}$   $[M+H]^+$  requires 425.1369).

#### 4.14. Antiarone L (43)

Colorless needles (acetone); mp. 131–133°C;  $[\alpha]_D^{25} -3.0^\circ$  ( $c$  0.53, MeOH); UV  $\lambda_{max}$  (MeOH)/nm (log  $\epsilon$ ) 328 (3.63, sh), 288 (4.31), 226 (4.44, sh), 206 (4.86); IR  $\nu_{max}/cm^{-1}$  (KBr) 3456, 3175, 2964, 2924, 1638, 1605, 1497, 1460, 1375, 1277, 1163, 1082; CD ( $c$  5.4 × 10<sup>-5</sup>, MeOH)  $[\theta]_{208} -9580$ ,  $[\theta]_{224} +38450$ ,  $[\theta]_{286} -22450$ ,  $[\theta]_{312} +52330$ ;  $^1H$  NMR (400 MHz, acetone- $d_6$ )  $\delta_H$  12.17 (1H, br s, D<sub>2</sub>O exchangeable, 5-OH), 9.69 (1H, br s, D<sub>2</sub>O exchangeable, 8-OH), 7.55 (1H, br s, D<sub>2</sub>O exchangeable, 3'-OH), 7.06 (1H, d,  $J$  = 8.4 Hz, H-6), 6.90 (1H, d,  $J$  = 8.4 Hz, H-5'), 5.96 (2H, s, H-6&8), 5.62 (1H, dd,  $J$  = 13.2, 2.8 Hz, H-2), 5.13 (1H, t,  $J$  = 6.4 Hz, H-2''), 3.86 (3H, s, OCH<sub>3</sub>), 3.52 (2H, d,  $J$  = 6.4 Hz, H-1''), 3.16 (1H, dd,  $J$  = 17.2, 13.2 Hz, H-3 $\alpha$ ), 2.66 (1H, dd,  $J$  = 17.2, 2.8 Hz, H-3 $\beta$ ), 1.67 & 1.63 (each 3H, s, H-4'' & 5'');  $^{13}C$  NMR (acetone- $d_6$ , 100 MHz)  $\delta_C$  197.4 (C-4), 167.2 (C-7), 165.1 (C-5), 164.4 (C-9), 148.0 (C-4'), 144.8 (C-3'), 131.4 (C-3''), 130.5 (C-1'), 126.9 (C-2'), 124.0 (C-2''), 118.2 (C-6'), 109.5 (C-5'), 103.0 (C-10), 96.7 (C-8), 95.7 (C-6), 79.9 (C-2), 56.2 (OCH<sub>3</sub>), 43.1 (C-3), 25.7 & 17.9 (C-4'' & 5''), 25.0 (C-1''); EIMS  $m/z$  370 (100%)  $[M]^+$ , 352 (10%), 219 (12%), 153 (26%), 125 (18%); HREIMS  $m/z$  370.1412 ( $C_{21}H_{22}O_6$   $[M]^+$  requires 370.1416).

#### 4.15. Antiarone K (44)

Colorless powder (acetone); mp 171–173 °C;  $[\alpha]_D^{25} -44.7^\circ$  ( $c$  0.001, MeOH); UV  $\lambda_{max}$  (MeOH)/nm (log  $\epsilon$ ) 324 (3.41, sh), 286 (4.06), 231 (4.35, sh), 213 (4.25); IR  $\nu_{max}/cm^{-1}$  (KBr) 3600–3000, 2963, 2926, 2855, 1639, 1522, 1466, 1456, 1340, 1271, 1161, 1085; CD ( $c$  5.0 × 10<sup>-5</sup>, MeOH)  $[\theta]_{210} -10580$ ,  $[\theta]_{229} +39460$ ,  $[\theta]_{290} -25380$ ,  $[\theta]_{314} +52190$ ;  $^1H$

NMR (acetone- $d_6$ , 400 MHz)  $\delta_H$  12.18 (1H, br s, D<sub>2</sub>O exchangeable, 5-OH), 7.70 (1H, br s, D<sub>2</sub>O exchangeable, 3'-OH), 6.56 (1H, s, H-6'), 6.40 (1H, d,  $J = 9.8$  Hz, H-1''), 5.95 (2H, s, H-6 & 8), 5.73 (1H, d,  $J = 9.8$  Hz, H-2''), 5.60 (1H, dd,  $J = 13.4, 2.6$  Hz, H-2), 5.13 (1H, t,  $J = 6.8$  Hz, H-2''), 3.48 (2H, d,  $J = 6.8$  Hz, H-1''), 3.17 (1H, dd,  $J = 17.0, 13.4$  Hz, H-3 $\alpha$ ), 2.64 (1H, dd,  $J = 17.0, 2.6$  Hz, H-3 $\beta$ ), 1.63 & 1.67 (each 3H, s, H-4'' & 5''), 1.18 & 1.20 (each 3H, s, 2'''-CH<sub>3</sub>  $\times$  2); <sup>13</sup>C NMR (acetone- $d_6$ , 100 MHz)  $\delta_C$  197.4 (C-4), 167.2 (C-7), 165.2 (C-5), 164.5 (C-9), 143.8 (C-3'), 140.5 (C-4'), 133.1 (C-5'), 131.3 (C-3'' & 3'''), 120.1 (C-1'), 127.1 (C-2'), 124.0 (C-2''), 122.7 (C-4'''), 120.0 (C-6'), 103.0 (C-10), 96.7 (C-8), 95.7 (C-6), 77.5 (C-2'''), 77.0 (C-2), 43.2 (C-3), 32.4 & 29.1 (C-2'''-CH<sub>3</sub>  $\times$  2), 25.7 & 17.9 (C-4'' & 5''), 25.2 (C-1''); EIMS  $m/z$  436 (100%) [M]<sup>+</sup>; 418 (10%), 286 (25%), 255 (18%); 153 (26%); HREIMS  $m/z$  436.1889 (C<sub>26</sub>H<sub>28</sub>O<sub>6</sub> [M]<sup>+</sup> requires 436.1886).

#### 4.16. In vitro cytotoxicity assay

The sulforhodamine B assay was used according to the procedures developed and validated at NCI.<sup>47</sup> Doxorubicin was used as the positive control antitumor drug. The in vitro anticancer activities are expressed as ED<sub>50</sub> values, which is the test compound concentration ( $\mu\text{g/mL}$ ) that reduced the cell number by 50% after 72 h of continuous treatment. The values were interpolated from dose-response data. Each test was performed in triplicate with variation less than 5%. The ED<sub>50</sub> values determined in each of independent tests varied less than 10%. Compound stock solutions were prepared in DMSO with the final solvent concentration 1% DMSO (v/v), a concentration without effect on cell replication. The cells were cultured at 37 °C in RPMI-1640 supplemented with 25 mM *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid (HEPES), 2% (w/v) sodium bicarbonate, 10% (v/v) fetal bovine serum, and 100  $\mu\text{g/mL}$  kanamycin in a humidified atmosphere containing 5% CO<sub>2</sub>.

#### Acknowledgments


The authors acknowledge financial support from the National Science Council, Taiwan, Republic of China awarded to T.S. Wu. Partial support was received from NIH Grant No. CA-177584-01 awarded to K.H. Lee.

#### References and notes


1. Newman RA, Yang P, Pawlus AD, Block KI. *Mol Interventions*. 2008; 8:36. and references therein.
2. Prassas I, Diamandis EP. *Nat Rev Drug Disc*. 2008; 7:926.
3. Shi LS, Liao YRM, Su J, Lee AS, Kuo PC, Damu AG, Kuo SC, Sun HD, Lee KH, Wu TS. *J Nat Prod*. 2010; 73:1214. and references therein. [PubMed: 20553004]
4. Liu Q, Tang JS, Hu MJ, Liu J, Chen HF, Gao H, Wang GH, Li SL, Hao XJ, Zhang XK, Yao XS. *J Nat Prod*. 2013; 76:1771. [PubMed: 24033101]
5. Hano Y, Mitsui P, Nomura T. *Heterocycles*. 1990; 30:1023.
6. Hano Y, Mitsui P, Nomura T. *Heterocycles*. 1990; 31:1315.
7. Hano Y, Mitsui P, Nomura T, Kawai T, Yoshida Y. *J Nat Prod*. 1991; 54:1049.
8. Dong WH, Mei WL, Zhao YX, Zeng YB, Zuo WJ, Wang H, Li XN, Dai HF. *Planta Med*. 2011; 77:1730. [PubMed: 21509716]
9. Dai HF, Gan YJ, Que DM, Wu J, Wen ZC, Mei WL. *J Asian Nat Prod Res*. 2009; 11:832. [PubMed: 20183332]
10. Dai HF, Gan YJ, Que DM, Wu J, Wen ZC, Mei ML. *Molecules*. 2009; 14:3694. [PubMed: 19783952]



11. Huang, KC. *The Pharmacology of Chinese Herbs*. CRC Press; Louisville: 1993. p. 60-61.
12. Uno Y, Mitsui P, Nomura T. *Jpn Kokai Tokkyo Koho JP04,169, 548 [92, 169, 548] (cl Co 7(49/84), 17, Jun 1992, Appl 90/295, 298, 02 Nov 1990, 599. [CA 117: P239819v (1992)]*.
13. Scott, AI. *Interpretation of the Ultraviolet Spectra of Natural Product*. Pergamon Press; New York: 1964. p. 235
14. Muehlradt P, Weiss Ek, Reichstein T. *Helv Chem Acta*. 1964; 47:2164.
15. Levrier C, Kiremire B, Guéritte F, Litaudon M. *Fitoterapia*. 2012; 83:660. [PubMed: 22348979]
16. Wehrli W, Schindler O, Reichstein T. *Helv Chem Acta*. 1962; 45:1183.
17. Peoghenghi R, Philipp A, Gaudry R. *Tetrahedron Lett*. 1963; 29:2045.
18. Scott, AI. *Interpretation of the Ultraviolet Spectra of Natural Product*. Pergamon Press; New York: 1964. p. 142
19. Chen IS, Chang CT, Sheen WS, Teng CM, Tsai IL, Duh CH, Ko FN. *Phytochemistry*. 1996; 41:525. [PubMed: 8821432]
20. Sharma RK, Negi DS, Gibbons S, Otsuka H. *Planta Med*. 2008; 74:175. [PubMed: 18240101]
21. Sano K, Yosioka I, Kitagawa I. *Chem Pharm Bull*. 1975; 23:20.
22. Antus S, Baitz-Gacs E, Kajtar J, Snatzke G, Tokes AL. *Liebigs Ann Chem*. 1994; 5:497.
23. Lei ZH, Nakayama H, Kuniyasu A, Tai BS, Nohara T. *Chem Pharm Bull*. 2002; 50:861. [PubMed: 12045350]
24. Juslen C. *Soc Sci Fennica, Commentationes Phys*. 1962; 2:61. [CA 57:15482i (1963)].
25. Wehrli W. *Helv Chem Acta*. 1962; 45:1206.
26. Muehlradt P, Weiss Ek, Reichstein T. *Ann Chem*. 1965; 685:253. [CA 63: 13389a (1964)].
27. Brandt R, Kaufmann H, Reichstein T. *Helv Chem Acta*. 1966; 49:2469.
28. Makarevich IF, Klimenko OI, Kolesnikov DG. *Chem Nat Compd*. 1974; 10:619–622.
29. Makarevich IF, Kolesnikov DG, Belokon VF. *Chem Nat Compd*. 1974; 10:616.
30. Carter CA, Gray EA, Schneider TL, Lovett CMJr, Scott L, Messer AC, Richardson DP. *Tetrahedron*. 1997; 53:16957.
31. Jimenez B, Grande MC, Anaya J, Torres P, Grande M. *Phytochemistry*. 2000; 53:1025. [PubMed: 10820825]
32. Ikeshiro Y, Mase I, Tomita Y. *Phytochemistry*. 1994; 35:1339. [PubMed: 7764824]
33. Harkar S, Razoan TK, Waight ES. *Phytochemistry*. 1984; 23:419.
34. Fukui H, Goto K, Tabata M. *Chem Pharm Bull*. 1988; 36:4174. [PubMed: 3245990]
35. Wu TS, Shi LS, Kuo SC. *Phytochemistry*. 1999; 50:1411.
36. Wu TS, Yeh JH, Wu PL. *Phytochemistry*. 1995; 40:121.
37. Evidente A, Andolfi A, Fiore M, Spanu E, Maddau L, Franceschini A, Marras F, Motta A. *J Nat Prod*. 2006; 69:671. [PubMed: 16643050]
38. Phadke PS, Rao AVR, Venkataraman K. *Indian J Chem*. 1967; 5:131.
39. Apsimon JW, Haymes NB, Sim KY, Whelley WB. *J Chem Soc*. 1963:3780.
40. Chen CY, Chang FR, Teng CM, Wu YC. *J Chin Chem Soc*. 1999; 46:77.
41. Kazuya K, Katsuyoshi M, Kazuo K, Taichi O. *Chem Pharm Bull*. 1994; 42:1669. [PubMed: 7954920]
42. Yadava VS, Misra K. *Indian J Chem Sect B*. 1989; 28:875.
43. Jacques R. *J Am Chem Soc*. 1987; 109:316.
44. Masao O, Masami T, Toru Y, Masami S, Yasumi U, Shunrou K. *J Agric Biol Chem*. 1989; 53:1469.
45. Rao KV. *J Heterocycl Chem*. 1975; 12:725.
46. The new cardiac glycosides (**1-8**) were obtained in minute quantity from *A. toxicaria*. Samples were sent for anti-inflammatory testing and insufficient quantities remained for cytotoxicity evaluation.
47. Rao KV, Kapicak LS. *J Heterocycl Chem*. 1976; 13:1073.



**Figure 1.**  
Chemical structures for new compounds.



**Scheme 1.**  
Biosynthetic pathway of cardiac glycosides.

**Table 1**  
**<sup>13</sup>C NMR data for antiartoxoside A-G (1-7) and antiarotoxinin B (8)**

Carbon	1 <sup>δ</sup>	2 <sup>δ</sup>	3 <sup>δ</sup>	4 <sup>δ</sup>	5	6	7 <sup>δ</sup>	8
1	36.3	26.9	25.3	26.9	26.7	22.0	23.6	25.8
2	22.4	28.7	27.4	28.6	27.9	26.4	26.8	28.6
3	72.9	73.9	73.8	73.8	73.2	72.3	74.1	67.8
4	32.1	35.6	34.8	35.6	35.1	30.0	36.1	36.1
5	72.9	74.7	73.1	74.2	74.3	30.4	73.4	74.5
6	43.3	35.8	35.1	35.9	36.5	33.2	40.8	37.8
7	28.4	24.3	24.5	24.8	24.7	26.0	21.3	24.4
8	42.3	40.7	41.3	40.4	40.4	48.2	41.2	39.0
9	41.0	40.2	39.4	37.5	37.7	42.0	37.3	40.0
10	55.7	74.4	74.4	74.7	74.4	34.0	39.2	41.3
11	23.5	21.6	22.8	30.8	30.7	22.1	26.1	22.0
12	39.9	40.0	40.4	74.7	74.7	39.7	31.4	40.3
13	50.2	50.1	50.3	56.7	56.9	50.1	51.9	47.8
14	84.8	84.6	85.0	85.0	85.1	83.8	86.7	83.8
15	33.4	33.0	33.0	33.4	33.4	32.2	33.7	33.1
16	27.2	27.5	27.2	27.9	29.2	22.1	34.3	19.0
17	51.5	51.3	51.3	46.4	46.2	51.4	87.8	51.5
18	16.3	16.3	16.3	10.3	10.3	16.4	13.1	15.5
19	176.7						17.0	17.4
20	176.1	176.3	176.4	176.7	176.8	176.0	174.0	71.1
21	73.8	73.8	73.8	74.0	74.1	73.6	73.8	65.8
22	117.6	117.7	117.6	117.5	117.4	117.6	116.6	
23	174.6	174.8	174.6	174.7	174.8	174.5	173.2	
1'	99.8	100.8	99.3	100.7	99.4	99.8	99.8	
2'	72.7	72.6	72.2	72.6	69.8	72.9	69.6	
3'	72.8	73.0	73.1	72.9	73.6	72.9	73.8	
4'	74.3	73.9	73.8	73.7	73.7	74.1	73.3	
5'	69.9	70.7	70.8	70.7	70.0	70.0	70.0	

Carbon	1 <sup>‡</sup>	2 <sup>‡</sup>	3 <sup>‡</sup>	4 <sup>‡</sup>	5	6	7 <sup>‡</sup>	8
δ'	18.6	18.6	18.8	18.6	17.0	18.6	17.3	

δ' Value in pyridine-*d*5 (100 MHz).

<sup>‡</sup> δ Value in pyridine-*d*5 (75 MHz).



**Table 2**  
**<sup>1</sup>H NMR data for antiarritoxioside A-G (1-7) and antiarritoxinin B (8)**

Proton	1	2 <sup>z</sup>	3	4	5	6	7	8
1a/b	1.76 (br d, 13.6)/3.29 (ddd, 13.6, 13.6, 5.7)	1.90 (m)/2.19 (m)	2.04 (m)/2.44 (m)	1.95 (m)/2.27 (br dd, 8.4, 2.3)	1.92 (m)/2.46 (br s dd, 14.5, 2.9)	1.23 (m)/2.07 (m)	1.32 (ddd, 13.5, 13.5, 3.8)/2.21 (m)	1.45 (t, 11.7)/2.21 (td, 12.5, 4.4)
2a/b	2.19 (m)/2.27 (m)	1.67 (m)/2.04 (m)	1.81 (m)/2.14 (m)	1.69 (br d, 14.8)/2.00 (m)	1.81 (br d, 13.1)/2.17 (m)	1.52 (m)	1.92 (m)/2.07 (m)	1.81 (m)
3	4.81 (dddd, 11.0, 11.0, 5.4, 5.4)	4.29 (br s, 6.6) <sup>†</sup>	4.40 (br s, 15.7) <sup>†</sup>	4.27 (br s, 7.9) <sup>†</sup>	4.48 (br s, 7.7) <sup>†</sup>	4.18 (br s, 9.9) <sup>†</sup>	4.52 (br s, 9.8) <sup>†</sup>	4.44 (br s, 11.3)
4a/b	2.19 (m)/2.45 (br d, 12.8)	1.90 (m)/2.11 (m)	1.81 (m)/2.04 (m)	1.97 (m)/2.15 (m)	1.92 (m)/2.09 (br d, 9.7)	1.23 (m)/1.48 (br t, 4.0)	1.56 (m)/1.97 (m)	1.78 (m)/2.32 (dd, 14.9, 2.5)
5						2.07 (m)		
6a/b	2.19 (m)/2.27 (m)	1.55 (m)/2.25 (m)	1.65 (m)/2.14 (m)	1.56 (dd, 11.2, 6.3)/1.97 (m)	1.63 (br d, 13.0)/2.28 (m)	1.78 (m)/2.02 (m)	1.49 (m)/2.07 (m)	1.62 (br d, 13.0)/2.03 (m)
7a/b	2.27 (m)/2.68 (br d, 11.8)	1.23 (m)/2.33 (br d, 9.8)	1.65 (m)/2.15 (m)	1.32 (br d, 13.2)/2.29 (br s dd, 9.9, 3.3)	2.12 (m)/2.32 (m)	1.55 (m)/1.78 (m)	1.30 (m)/1.64 (br t, 13.5)	1.40 (m)/2.36 (td, 13.3, 2.0)
8	2.27 (m)	2.36 (d, 12.3)	2.15 (m)	2.48 (br t, 11.8)	2.48 (br dd, 12.8, 2.9)	1.29 (m)	1.99 (m)	1.76 (dt, 12.2, 11.8)
9	2.27 (m)	1.63 (m)	1.65 (m)	1.78 (ddd, 8.7, 8.7, 3.0)	1.81 (br d, 13.1)	1.24 (m)	2.39 (m)	2.03 (m)
10						1.43 (m)		
11a/b	1.88 (m)	1.55 (m)/1.90 (m)	1.38 (m)/2.26 (m)	2.15 (m)/2.24 (m)	2.12 (m)/2.25 (m)	1.66 (br d, 2.3)/1.84 (m)	1.84 (br t, 13.9)/2.25 (m)	1.40 (m)
12a/b	1.46 (m)	1.40 (m)	1.38 (m)	-3.74 (br t, 7.8)	-3.76 (br t, 9.7)	1.31 (m)	2.17 (m)/2.39 (m)	1.42 (t, 11.9)
15a/b	1.93 (m)/2.19 (m)	1.90 (m)/2.04 (m)	1.81 (m)/2.04 (m)	1.73 (m)/1.97 (m)	1.92 (m)	1.35 (m)	1.19 (m)/1.49 (m)	1.89 (m)/2.09 (dt, 12.6, 9.8)
16a/b	1.93 (m)/2.03 (dd, 20.0, 10.8)	2.04 (m)	1.81 (m)/2.04 (m)	2.15 (m)	2.12 (m)	1.94 (m)/2.07 (m)	1.97 (m)/2.21 (m)	1.92 (m)/2.26 (m)
17	2.76 (dd, 9.1, 3.2)	2.78 (br d, 7.7)	2.79 (br t, 2.5)	3.76 (br t, 7.4)	3.76 (br t, 9.7)	2.76 (br d, 8.8)		2.21 (m)
18	0.98 (s)	1.05 (s)	1.15 (s)	1.28 (s)	1.29 (s)	0.99 (s)	1.26 (s)	1.31 (s)
19							1.17 (s)	1.19 (s)
20								4.36 (t, 6.5)
21a/b	4.98 (d, 18.1)/5.27 (d, 18.1)	5.13 (d, 18.2)/5.30 (d, 18.2)	5.01 (d, 18.0)/5.29 (d, 18.0)	5.09 (d, 17.9)/5.23 (d, 17.9)	5.03 (d, 18.1)/5.33 (d, 18.1)	5.02 (d, 17.8)/5.31 (br d, 17.8)	5.07 (dd, 18.2, 1.4)/5.21 (dd, 18.2, 1.4)	3.89 (dd, 10.5, 6.1)/4.08 (dd, 10.5, 7.2)
22	6.08 (s)	6.12 (s)	6.12 (s)	6.22 (s)	6.23 (s)	6.12 (s)	6.23 (d, 1.4)	
1'	5.44 (br s)	5.49 (br s)	5.40 (d, 5.8)	5.33 (br s)	5.43 (d, 8.1)	5.41 (br s)	5.39 d, 8.1)	

Proton	1	2 <sup>‡</sup>	3	4	5	6	7	8
2'	4.27 (br s)	4.54 (br s)	3.96 (d, 4.7)	4.48 (br s)	4.50 (dd, 8.1, 3.1)	4.54 (m)	4.46 (br d, 8.1)	
3'	4.44 (dd, 8.9, 3.4)	4.44 (dd, 9.0, 3.2)	4.67 (m)	4.38 (dd, 8.6, 2.8)	4.77 (t, 3.1)	4.54 (m)	4.70 (m)	
4'	4.19 (dd, 8.9, 8.9)	4.31 (m)	3.66 (d, 6.2)	4.21 (br t, 8.6)	4.13 (d, 3.1)	4.29 (m)	4.11 (br s)	
5'	4.32 (dq, 8.9, 6.1)	4.22 (m)	4.34 (dq, 6.2, 4.6)	4.18 (dq, 8.6, 5.9)	4.61 (q, 6.6)	4.29 (m)	4.59 (q, 6.4)	
6'a/b	1.59 (d, 6.1)	1.63 (d, 6.0)	1.59 (d, 4.6)	1.61 (d, 5.9)	1.53 (d, 6.6)	1.67 (d, 4.7)	1.56 (d, 6.4)	

$\delta$  Value in pyridine-*d*5 (400 MHz), coupling constants in Hz are given in parentheses.

<sup>‡</sup>  $W_{1/2}$  (Hz); width of 1/2 peak high.

<sup>‡</sup>  $\delta$  Value in pyridine-*d*5 (300 MHz), coupling constants in Hz are given in parentheses.

Table 3

Cytotoxicity (ED<sub>50</sub> µg/mL) of isolated compounds from *A. toxicaria*<sup>a</sup>

Compound	KB*	KB-VIN	A549	MCF-7	U-87-MG	PC-3	IA9	CAKI-1	HCT-9	S-KMEL-2
11	0.054	0.020	0.012	0.018	0.082	0.021	0.012	0.014	0.044	0.017
12	0.0097	0.068	0.044	0.063	0.15	0.078	0.020	0.018	0.090	0.073
14	1.5	1.7	0.12	0.58	1.9	0.60	0.53	0.51	0.94	0.16
15	2.7	3.0	0.14	0.69	2.9	0.81	0.66	0.67	6.4	0.57
16	0.025	0.014	0.0040	0.012	0.036	0.013	0.0076	0.0061	0.020	0.014
17	0.45	0.50	0.050	0.21	0.50	0.15	0.12	0.11	0.46	0.70
19	0.61	0.69	0.11	0.38	0.72	0.17	0.15	0.14	0.51	0.13
20	0.014	0.013	0.0027	0.0065	0.014	0.094	0.030	0.0031	0.0014	0.0013
21	0.066	0.051	0.016	0.042	0.078	0.052	0.013	0.014	0.067	0.064
22	0.044	0.018	0.0092	0.015	0.054	0.018	0.012	0.014	0.044	0.015
23	0.081	0.050	0.015	0.024	0.043	0.063	0.013	0.014	0.085	0.063
24	0.2	0.18	0.070	0.15	0.40	0.095	0.072	0.071	0.20	0.42
25	0.12	0.083	0.038	0.096	0.15	0.084	0.057	0.065	0.13	0.12
27	1.5	1.6	0.48	1.4	1.7	0.42	0.39	0.32	1.5	0.26
28	1.7	1.9	0.38	1.0	4.2	0.53	0.74	0.93	1.9	0.31
29	0.30	0.32	0.080	0.19	0.37	0.11	0.076	0.073	0.18	0.62
30	5.3	5.1	0.59	1.3	4.6	1.2	0.12	1.3	4.5	0.41
31	0.14	0.15	0.059	0.10	0.017	0.0044	0.058	0.072	0.15	0.13
32	0.065	0.075	0.046	0.12	0.15	0.085	0.062	0.068	0.11	0.12
33	0.13	0.14	0.058	0.092	0.13	0.091	0.063	0.070	0.11	0.12
34	0.067	0.061	0.013	0.018	0.071	0.050	0.014	0.015	0.066	0.065
35	0.49	0.57	0.070	0.42	0.73	0.16	0.13	0.13	0.35	0.12
36	1.8	2.2	0.54	1.3	4.5	0.89	0.97	1.2	3.4	0.32
37			5.3	17.5						
38	5.9	7.1	0.76	3.1	7.3	1.8	1.4	1.5	2.5	1.3
39	2.0	2.3	0.36	1.3	3.6	0.90	0.83	1.1	2.9	0.30
40			4.3	15.0						
41			10.8	>20		1.5	1.5	1.5	6.7	1.3

Compound	KB*	KB-VIN	A549	MCF-7	U-87-MG	PC-3	1A9	CAKI-1	HCT-9	S-KMEL-2
<b>42</b>	5.8	4.1	1.2	3.1	7.4					
<b>45</b>			>20	>20						

<sup>a</sup> Compounds **1–9** were not tested due to insufficient quantities remaining.

\* Cell line, ED50 in µg/mL.